Clinical trials
Autoimmune Liver Disease clinical trials
Below are recruiting autoimmune liver disease clinical trials, each written for real people, not researchers. We’re tracking 180 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06823713RecruitingPhase 1/Phase 2
Engineered immune cells for liver cirrhosis
This trial tests a personalized cell therapy made from your own white blood cells (called macrophages) that are engineered to help reduce scarring and inflammation in the liver. It is for people with liver cirrhosis due to fatty liver disease who have recently had a serious liver complication or need frequent fluid drainage.
BarcelonaAges 18–75 - NCT06983964Recruiting
CAR-T cell therapy for autoimmune diseases that haven't improved
This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.
Beijing, Beijing MunicipalityAges 18–65 - NCT06993493Recruiting
Car-T therapy for hard-to-treat autoimmune diseases
This trial tests whether a patient's own engineered immune cells (called CD19 CAR-T cells) can calm down overactive immune attacks in several autoimmune diseases like lupus, scleroderma, and myositis. It's for people whose disease isn't controlled by standard treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT07059169Recruiting
CAR-T cell therapy for severe autoimmune diseases
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT07193667Recruiting
CAR-T therapy for autoimmune diseases
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Shenyang, LiaoningAges 18–65 - NCT07193927RecruitingPhase 2
Testing a probiotic mix for fatty liver disease (MASLD)
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
Girona, GironaAges 18–75 - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT03178630Recruiting
MRI scans to track outcomes in children with autoimmune liver disease
This study uses MRI scans to find “biomarkers,” or imaging clues, that may help predict how autoimmune liver conditions will progress in children and young adults. If you qualify, you may get MRI imaging to see whether it relates to future health outcomes.
Cincinnati, OhioAges 6–23 - NCT07408336RecruitingEarly Phase 1
Study of AFN50 injection for active lupus
This study tests an investigational injection called AFN50 for people whose lupus (SLE) remains active despite standard treatments. The goal is to see if the drug can safely help control lupus symptoms better than current therapies alone.
Hefei, AnhuiAges 18–69 - NCT07588854Recruiting
Liver Stiffness Testing and Biopsy for Chronic Liver Disease
This study compares two non-invasive ultrasound methods (EUS-SWQ and FibroScan) with liver biopsy to see how well they detect liver scarring in patients with chronic liver disease. The goal is to improve how doctors diagnose and monitor liver damage from conditions like hepatitis B and fatty liver disease.
ShanghaiAges 18–80 - NCT07275736RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
BeijingAges 18–75 - NCT06825559RecruitingPhase 1
Saroglitazar safety in moderate liver impairment from cholestatic disease
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
Indianapolis, IndianaAges 18–80 - NCT04106518Recruiting
Genetics study of alcohol-related liver disease and cirrhosis
This study looks at genetic differences in people with alcohol-related liver illness, including a recent jaundice episode (alcoholic hepatitis). By following people over time, it may help doctors better predict illness and understand why some people develop worse liver problems.
AngersAges 18 years+ - NCT01280825Recruiting
Testing how to use genetic medicine results in routine care
This study looks at how to put genetic testing results (pharmacogenomics) into regular doctor care. It aims to see whether using the results helps doctors choose safer, better-matched medications.
Chicago, IllinoisAges 18 years+ - NCT06944353Enrolling by invitation
Fatty liver risk screening in the emergency department
This study looks at fatty liver findings on emergency department scans. If you have fatty liver and were sent home from the ED, the study may help connect you to follow-up care and avoid future liver problems.
Chicago, IllinoisAges 18 years+ - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT07359742Recruiting
Detecting liver scarring in chronic liver disease
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
BrusselsAges 18 years+ - NCT07452744Enrolling by invitation
Picroliv for non-alcoholic fatty liver disease
This study tests a plant-based medicine called Picroliv for people with non-alcoholic fatty liver disease (NAFLD). It aims to see if it is safe and can reduce fat in the liver.
Chandigarh, ChandigarhAges 18–60 - NCT04400604Recruiting
Study of liver disease risk from heavy alcohol use
This study looks at people with heavy alcohol use who may have alcohol-related liver damage. It aims to better understand liver disease risk and how it changes over time, using blood tests, some scans, and possibly stored tissue.
LilleAges 18–75 - NCT07699380RecruitingPhase 2
Metabolic study to improve insulin sensitivity in type 1 diabetes
This study tests a new medication to see if it can improve how your body responds to insulin and boost your cells' energy (mitochondrial function). It is for adults with type 1 diabetes who are already on insulin and have good overall health.
Seattle, WashingtonAges 18–69 - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT07400367Recruiting
Probiotics and lifestyle changes for fatty liver disease
This trial tests whether taking probiotics plus making lifestyle changes can improve fatty liver and metabolic health. You may qualify if you have liver fat and at least one sign of metabolic problems like high blood sugar or high blood pressure.
New Taipei CityAges 18–80
Hear when a new Autoimmune Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune liver disease?
- Yes. Clin2 currently lists 180 recruiting autoimmune liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.